Tumor modifier genes

Clinical and Translational Oncology

Volumn 4, Issue 7, 2002, Pages 349-357

  Fernández Piqueras, José ^a   Hernández, Javier Santos ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Functional polymorphisms; Mouse models; Tumor modifier genes

Indexed keywords

EID: 78649791184     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: None     Document Type: Article

References (106)

1. Macleod K. Tumor suppressor genes. Curr Opin Genet Dev 2000;10:81-93.
2. Fearon ER. Human cancer syndromes: clues to the origin and nature of cancer. Science 1997;278:1043-50.
3. Perera F P. Environment and cancer: who are susceptible? Science 1997;278:1068-73.
4. Ponder BAJ. Cancer Genetics. Nature 2001;411:336-41.
5. Dragani TA, Canzian F, Pierotti MA. A polygenic model of inherited predisposition to cancer. FASEB J 1996;10: 865-70.
6. Balmain A, Nagase H. Cancer resistance genes in mice: models for the study of tumor modifiers. Trends Genet 1998;14:139-44.
7. Balmain A. Cancer as a complex genetic trait: tumor susceptibility in humans and mouse models. Cell 2002; 108:145-52.
8. Nagase H, Mao JH, de Koning JP, et al. Epistatic interactions between skin tumor modifier loci in interspecific (spretus/musculus) backcross mice. Cancer Res 2001;61:1305-8.
9. Phelan CM, Rebbeck TR, Weber BL, et al. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nature Genet 1996;12:309-11.
10. Lacken SJ, Petersen GM, Gruber SB, et al. Familial co-lorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nature Genet 1997;17:79-83.
11. Zhang SL, DuBois W, Ramsay ES, et al. Efficiency alle-les of the Pctr1 modifier locus for plasmacytoma susceptibility. Mol Cell Biol 2001;21:310-8.
12. Taioli E, Crofts F, Trachman J, et al. Radical differences in CYP1A1 genotype and function. Toxicol (Letter) 1995; 77: 357-62.
13. Taioli E, Crofts F, Trachman J, et al. A specific African-American CYP1A1 polymorphism is associated with adenocarcinoma of lung. Cancer Res 1995;55: 472-3.
14. Kawajiri K, Eguchi H, Nakachi K, et al. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res 1996;56:72-6.
15. Sivaraman L, Leatham MP, Yee J, et al. CYP1A1 genetic polymorphisms and in situ colorectal cancer. Cancer Res 1994;54:3692-5.
16. Taioli E, Trachman J, Cheng X, et al. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res 1995;55:3757-8.
17. Liu YH, Taylor J, Linko P, et al. Glutathione S-transfe-rase mu in human lymphocyte and liver: role in modulating formation of carcinogen-derived DNA adducts. Carcinogenesis 1991;12:2269-75.
18. Board P, Coggan M, Johnston P, et al. Genetic heterogeneity of the human glutathione transferases: a complex of gene families. Pharmacol Ther 1990;48:357-69.
19. Skoda RC, Demierre A, McBride OW, et al. Human mi-crosomal xenobiotic epoxide hydrolase. Complementary DNA sequence, complementary DNA-directed expression in COS-1 cells and chromosomal localization. J Biol Chem 1988;263:1549-54.
20. Brockmoller J, Kerb R, Drakoulis N, et al. Genotype and phenotype of glutathione S-transferase class mu isoenzymes mu and psi in lung cancer patients and controls. Cancer Res 1993;53:1004-11.
21. Hassett C, Aicher L, Sidhu JS, et al. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet 1994;3:421-8.
22. McGlynn KA, Rosvold EA, Lustbader ED, et al. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc Natl Acad Sci USA 1995; 92:2384-7.
23. Aktas D, Ozen H, Atsu N, et al. Glutathione S-transfera-se M1 gene polymorphism in bladder cancer patients. A marker for invasive bladder cancer? Cancer Genet Cy-togenet 2001;125:1-4.
24. Hong YJ, Lee JK, Lee GH, et al. Influence of glutathione S-transferase M1 and T1 genotypes on larynx cancer risk among Korean smokers. Clin Chem Lab Med 2000;38:917-9.
25. Lazarus P, Sheikh SN, Ren Q, et al. p53, but not p16 mutations in oral squamous cell carcinomas are associated with specific CYP1A1 and GSTM1 polymorphic genotypes and patient tobacco use. Carcinogenesis 1998;19:509-14.
26. Maugard CM, Charrier J, Pitard A, et al. Genetic polymorphism at the glutathione S-transferase (GST) P1 locus is a breast cancer risk modifier. Int J Cancer 2001; 91:334-9.
27. Hayashi S, Watanabe J, Kawajiri K, et al. High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and Mu-class glutathione S-transfe-rase genes. Cancer Res 1992;83:866-70.
28. Vineis P, Bartsch H, Caporaso N, et al. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 1994;369:154-6.
29. Chu G. Double strand break repair. J Biol Chem 1997; 272:24097-100.
30. Jeggo PA. Identification of genes involved in repair of DNA double-strand breaks in mammalian cells. Radiat Res 1998;150:S80-91.
31. Karran P. DNA double strand break repair in mammalian cells. Curr Opin Genet Dev 2000;10:144-50.
32. Gottlieb TM, Jackson S P. The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen. Cell 1993;72:131-42.
33. Kurimasa A, Ouyang H, Dong LJ, et al. Catalytic subunit of DNA-dependent protein kinase: impact on lymphocyte development and tumorigenesis. Proc Natl Acad Sci USA 1999;96:1403-8.
34. Lieberman M, Hansteen GA, Waller EK, et al. Unexpected effects of the severe combined immunodeficiency mutation on murine lymphomagenesis. J Exp Med 1992;176:399-405.
35. Okayasu R, Suetomi K, Yu Y, Silver A, Bedford JS, Cox R, Ullrich RL. A deficiency in DNA repair and DNA-PKcs expression in the radiosensitive BALB/c mouse. Cancer Res 2000;60:4342-5.
36. Mori N, Matsumoto Y, Okumoto M, et al. Variations in Prkdc encoding the catalytic subunit of DNA-depen-dent protein kinase (DNA-PKcs) and susceptibility to radiation-induced apoptosis and lymphomagenesis. Oncogene 2001;20:3609-19.
37. Chen J, Giovannucci E, Kelsey K, et al. A methylenete-trahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996;56:4862-4.
38. Ma J, Stampfer MJ, Giovannucci E, et al. Methylenete-trahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997;57:1098-102.
39. Esteller M, García A, Martínez-Palones JM, et al. Germ line polymorphisms in cytochrome-P450 1A1 (C4887CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility. Carcinogenesis 1997;18:2307-11.
40. Matsuo K, Suzuki R, Hamajima N, et al. Association between polymorphisms of folate-and methionine-me-tabolizing enzymes and susceptibility to malignant lymphoma. Blood 2001;97:3205-9.
41. Garland C, Shekelle RB, Barrett-Connor E, et al. Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet 1985; 1:307-9.
42. Smith EL, Walworth NC, Holick MF. Effect of 1, 25-dihydroxy vitamin D3 on the morphological and biochemical differentation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol 1987;86:709-14.
43. Díaz GD, Paraskeva C, Thomas MG, et al. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res 2000;60:2304-12.
44. Park WH, Seol JG, Kim ES, et al. Cell cycle arrest induced by the vitamin D(3) analog EB1089 in NCI-H929 myeloma cells is associated with induction of the cy-clin-dependent kinase inhibitor p27. Exp Cell Res 2000; 254: 279-86.
45. McDonald PN, Kraichely DM, Brown AJ. The vitamin D receptor. En: Burris TP, McCabe ERB, editors. Nuclear receptor and Genetic disease. Orlando FL: Academic Press Inc.; 2001. p. 197-243.
46. Stumpf WE, Sar M, Reid FA, et al. Target cells for 1, 25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 1979;206: 1188-90.
47. Ingles SA, Ross RK, Yu MC, et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997;89:166-70.
48. Palmer HG, González-Sancho JM, Espada J, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 2001;154: 369-87.
49. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994;22:3181-6.
50. Dietrich WF, Lander ES, Smith JS, et al. Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell 1993;75:631-9.
51. Su LK, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992;256:668-70.
52. Moser AR, Dove WF, Roth KA, et al. The Min (multiple intestinal neoplasia) mutation: its effect on gut epithelial cell differentiation and interaction with a modifier system. Cell Biol 1992;116:1517-26.
53. Min-induced intestinal neoplasia. Cell 1995;81:957-66.
54. Cormier RT, Hong KH, Halberg RB, et al. Secretory phospholipase Pla2g2ag2a confers resistance to intestinal tumorigenesis. Nature Genet 1997;17:88-91.
55. Macleod KF, Jacks T. Insights into cancer from transge-nic mouse models. J Pathol 1999; 187: 43-60.
56. Kervinen K, Sodervik H, Makela J, et al. Is the development of adenoma and carcinoma in proximal colon related to apolipoprotein E phenotype? Gastroenterology 1996;110:1785-90.
57. Doll R. Epidemiological evidence of the effects of behaviour and the environment on the risk of human cancer. Recent Results Cancer Res 1998;154:3-21.
58. Matsuo K, Hamajima N, Shinoda M, et al. Gene-environment interaction between an aldehyde dehydroge-nase-2 (ALDH2) polymorphism and alcohol consumption for the risk of esophageal cancer. Carcinogenesis 2001;22:913-6.
59. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of andro-gens and progesterone. J Natl Cancer Inst 1998;90: 1774-86.
60. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92:1472-89.
61. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-85.
62. Emons G, Fleckenstein G, Hinney B, et al. Hormonal interactions in endometrial cancer. Endocr Relat Cancer 2000;7:227-42.
63. Foster JS, Henley DC, Ahamed S, et al. Estrogens and cell-cycle regulation in breast cancer. Trends Endocri-nol Metab 2001;12:320-7.
64. Jernstrom H, Deal C, Wilkin F, et al. Genetic and non-genetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premeno-pausal women. Cancer Epidemiol Biomarkers Prev 2001;10:377-84.
65. Strewler GJ. The physiology of parathyroid hormone-related protein. N Engl J Med 2000;34:177-85.
66. Manenti G, Peissel B, Gariboldi M, et al. A cancer modifier role for parathyroid hormone-related protein. Oncogene 2000;19:5324-8.
67. Suganuma M, Okabe S, Sueoka E, et al. A new process of cancer prevention mediated through inhibition of tumor necrosis factor alpha expression. Cancer Res 1996; 56:3711-5.
68. Cordon-Cardo C, Prives C. At the crossroads of inflammation and tumorigenesis. J Exp Med 1999;15:190(10): 1367-70.
69. Suganuma M, Okabe S, Marino MW, et al. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res 1999;59:4516-8.
70. Moore RJ, Owens DM, Stamp G, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carci-nogenesis. Nature Med 1999;5:828-31.
71. Tsukasaki K, Miller CW, Kubota T, et al. Tumor necrosis factor alpha polymorphism associated with increased susceptibility to development of adult T-cell leuke-mia/lymphoma in human T-lymphotropic virus type 1 carriers. Cancer Res 2001;61:3770-4.
72. El-Omar EM, Carrington M, Chow WH, et al. Interleu-kin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000;404:398-402.
73. Esteller M, Corn PG, Baylin SB, et al. A gene hyper-methylation profile of human cancer. Cancer Res 2001; 61:3225-9.
74. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
75. Frayling IM, Beck NE, Ilyas M, et al. The APC variants I1307K and E1317Q are associated with colorectal tumors, but not always with a family history. Proc Natl Acad Sci U S A 1998;95(18):10722-7.
76. Woodage T, King SM, Wacholder S, et al. The AP-CI1307K allele and cancer risk in a community-based study of Ashkenazi Jews. Nature Genet 1998;20:62-5.
77. Bala S, Peltomaki P. CYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res 2001;61:6042-5.
78. Wang L, Habuchi T, Takahashi T, et al. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis 2002;23:257-64.
79. Zhang YJ, Chen SY, Chen CJ, Santella RM. Polymorphisms in cyclin D1 gene and hepatocellular carcinoma. Mol Carcinog 2002;33:125-9.
80. Marin MC, Jost CA, Brooks LA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nature Genet 2000;25:47-54.
81. Contente A, Dittmer A, Koch MC, et al. A polymorphic microsatellite that mediates induction of PIG3 by p53. Nature Genet 2002;30:315-20.
82. Moen CJ, Groot PC, Hart AA, et al. Fine mapping of colon tumor susceptibility (Scc) genes in the mouse, different from the genes known to be somatically mutated in colon cancer. Proc Natl Acad Sci USA 1996;93:1082-6.
83. van Wezel T, Stassen AP, Moen CJ, et al. Gene interaction and single gene effects in colon tumour susceptibility in mice. Nature Genet 1996;14:468-70.
84. van Wezel T, Ruivenkamp CA, Stassen AP, et al. Four new colon cancer susceptibility loci, Scc6 to Scc9 in the mouse. Cancer Res 1999;59:4216-8.
85. Lee GH, Bennett LM, Carabeo RA, et al. Identification of hepatocarcinogen-resistance genes in DBA/2 mice. Genetics 1995;139:387-95.
86. Gariboldi M, Manenti G, Canzian F, et al. Chromosome mapping of murine susceptibility loci to liver carcino-genesis. Cancer Res 1993;53 209-11.
87. Manenti G, Binelli G, Gariboldi M, et al. Multiple loci affect genetic predisposition to hepatocarcinogenesis in mice. Genomics 1994;23:118-24.
88. Gariboldi M, Manenti G, Canzian F, et al. A major susceptibility locus to murine lung carcinogenesis maps on chromosome 6. Nature Genet 1993;3:132-6.
89. Manenti G, Gariboldi M, Elango R, et al. Genetic mapping of a pulmonary adenoma resistance (Par1) in mouse. Nature Genet 1996; 12:455-7.
90. Manenti G, Gariboldi M, Fiorino A, et al. Genetic mapping of lung cancer modifier loci specifically affecting tumor initiation and progression. Cancer Res 1997;57:4164-6.
91. Mock BA, Krall MM, Dosik JK.Genetic mapping of tumor susceptibility genes involved in mouse plasmacyto-magenesis. Proc Natl Acad Sci U S A 1993;90:9499-503.
92. Potter M, Mushinski EB, Wax JS, et al. Identification of two genes on chromosome 4 that determine resistance to plasmacytoma induction in mice. Cancer Res 1994; 54:969-75.
93. Nagase H, Bryson S, Cordell H, et al. Distinct genetic loci control development of benign and malignant skin tumours in mice. Nature Genet 1995;10:424-9.
94. Nagase H, Mao JH, Balmain A. A subset of skin tumor modifier loci determines survival time of tumor-bearing mice. Proc Natl Acad Sci U S A 1999;96:15032-7.
95. Okumoto M, Nishikawa R, Imai S, et al. Genetic analysis of resistance to radiation lymphomagenesis with recombinant inbred strains of mice. Cancer Res 1990;50: 3848-50.
96. Mori N, Okumoto M, Yamate J. A susceptibility locus for radiation lymphomagenesis on mouse chromosome 16. J Radiat Res 2000;41:367-72.
97. Saito Y, Ochiai Y, Kodama Y, et al. Genetic loci controlling susceptibility to g-ray-induced thymic lymphoma. Oncogene 2001;20:5243-7.
98. Angel JM, Morizot DC, Richie ER. Localization of a novel chromosome 7 locus that suppresses development of N-methyl-N-nitrosourea-induced murine thymic lymphomas. Mol Carcinog 1993;7:151-6.
99. Wielowieyski A, Brennan LA, Jongstra J. Tli1, a resistance locus for carcinogen-induced T-lymphoma. Mamm Genome 1999;10:623-7.
100. Lander ES, Botstein D. Mapping mendelian factors underlying quantitative traits using RFLP linkage maps. Genetics 1989;121:185-99.
101. Demant P. Genetic resolution of susceptibility to cancer- new perspectives. Semin Cancer Biol 1992;3:159-66.
102. Saran A, Zaffaroni D, Pazzaglia S, et al. Inhibition of both skin and lung tumorigenesis by Car-R mouse derived cancer modifier loci. Int J Cancer 2002;97: 580-3.
103. Nadeau JH, Singer JB, Matin A, et al. Analysing complex genetic traits with chromosome substitution strains. Nature Genet 2000;24:221-5.
104. Matin A, Collin GB, Asada Y, et al. Susceptibility to tes-ticular germ-cell tumours in a 129.MOLF-Chr 19 substitution strain. Nature Genet 1999;23:237-40.
105. Santos J, Montagutelli X, Acevedo A, et al. A new locus for resistance to g-radiation-induced thymic lymphoma identified using inter-specific consomic and inter-specific recombinant congenic strains of mice. Oncogene (in press).
106. Dragani TA, Manenti G. Mom1 leads the pack. Nature Genet 1997;17:7-8.